Compare
Replimune Group, Inc. vs Prime Medicine, Inc. vs Taysha Gene Therapies, Inc. vs Fate Therapeutics Inc
| Latest fiscal year | Replimune Group, Inc. REPL | Prime Medicine, Inc. PRME | Taysha Gene Therapies, Inc. TSHA | Fate Therapeutics Inc FATE |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $4.63M | $9.77M | $6.65M |
| Revenue growth (YoY) | n/a | +55.3% | +17.3% | -51.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/m | n/m |
| Net margin | n/a | n/m | n/m | n/m |
| Net income | -$313.94M | -$201.14M | -$109.00M | -$136.31M |
| EPS (Diluted) | -$3.38 | -$1.35 | -$0.34 | -$1.15 |
| Operating cash flow | -$280.34M | -$162.56M | -$93.09M | -$106.08M |
| Free cash flow | -$284.57M | -$167.09M | -$93.83M | -$112.04M |
| Cash & equivalents | $209.02M | $63.03M | $319.77M | $46.63M |
| Total assets | $332.39M | $342.73M | $343.32M | $318.94M |
| Total liabilities | $166.23M | $221.87M | $96.38M | n/a |
| Shareholders' equity | $166.16M | $120.87M | $246.94M | $207.18M |
| Return on year-end equity | -188.9% | -166.4% | -44.1% | -65.8% |
| Shares outstanding | 82.72M | 180.51M | 285.05M | 115.36M |
Revenue, most recent five fiscal years
| Fiscal year | Replimune Group, Inc. | Prime Medicine, Inc. | Taysha Gene Therapies, Inc. | Fate Therapeutics Inc |
|---|---|---|---|---|
| Latest | n/a | $4.63M Ended 2025-12-31 | $9.77M Ended 2025-12-31 | $6.65M Ended 2025-12-31 |
| 1 year earlier | n/a | $2.98M Ended 2024-12-31 | $8.33M Ended 2024-12-31 | $13.63M Ended 2024-12-31 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $15.45M Ended 2023-12-31 | $63.53M Ended 2023-12-31 |
| 3 years earlier | n/a | $0 Ended 2022-12-31 | $2.50M Ended 2022-12-31 | $96.30M Ended 2022-12-31 |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | n/a | $55.85M Ended 2021-12-31 |